0001209191-20-010541.txt : 20200219
0001209191-20-010541.hdr.sgml : 20200219
20200219163349
ACCESSION NUMBER: 0001209191-20-010541
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20200217
FILED AS OF DATE: 20200219
DATE AS OF CHANGE: 20200219
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Kewalramani Reshma
CENTRAL INDEX KEY: 0001735944
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 000-19319
FILM NUMBER: 20630286
MAIL ADDRESS:
STREET 1: C/O VERTEX PHARMACEUTICALS, INC.
STREET 2: 50 NORTHERN AVENUE
CITY: BOSTON
STATE: MA
ZIP: 02210
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: VERTEX PHARMACEUTICALS INC / MA
CENTRAL INDEX KEY: 0000875320
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 043039129
STATE OF INCORPORATION: MA
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 50 NORTHERN AVENUE
CITY: BOSTON
STATE: MA
ZIP: 02210
BUSINESS PHONE: 6173416393
MAIL ADDRESS:
STREET 1: 50 NORTHERN AVENUE
CITY: BOSTON
STATE: MA
ZIP: 02210
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2020-02-17
0
0000875320
VERTEX PHARMACEUTICALS INC / MA
VRTX
0001735944
Kewalramani Reshma
C/O VERTEX PHARMACEUTICALS INCORPORATED
50 NORTHERN AVENUE
BOSTON
MA
02210
1
1
0
0
EVP and CMO
Common Stock
2020-02-17
4
F
0
944
241.50
D
34341
D
Common Stock
2020-02-18
4
S
0
120
241.71
D
34221
D
Common Stock
2020-02-18
4
S
0
540
242.62
D
33681
D
Common Stock
2020-02-18
4
S
0
134
243.76
D
33547
D
Common Stock
2020-02-18
4
S
0
260
244.94
D
33287
D
Common Stock
2020-02-18
4
S
0
129
245.75
D
33158
D
Transaction made pursuant to Dr. Kewalramani's company approved trading plan under Rule 10b5-1.
Open market sales reported on this line occurred at a weighted average price of $241.71 (range $241.24 to $242.02).
Dr. Kewalramani undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price.
Open market sales reported on this line occurred at a weighted average price of $242.62 (range $242.25 to $243.21).
Open market sales reported on this line occurred at a weighted average price of $243.76 (range $243.25 to $244.08).
Open market sales reported on this line occurred at a weighted average price of $244.94 (range $244.36 to $245.32).
Open market sales reported on this line occurred at a weighted average price of $245.75 (range $245.36 to $245.86).
/s/ Omar White, Attorney-in-Fact
2020-02-19